Nazim Arain Shares The New Standard: Anticoagulation in Cirrhosis
Nazim Arain, Consultant Internal Medicine and Gastroenterologist at Almana Group of Hospitals, shared on LinkedIn:
”Anticoagulation in Cirrhosis: The New Standard
Patients with cirrhosis face an increased risk of thrombotic events like AF and VTE.
It’s now accepted that their coagulation is “rebalanced,” making anticoagulation the standard of care to reduce stroke/thrombosis risk!
The primary bleeding risk is linked to portal hypertension, NOT general clotting deficiency.
Direct Oral Anticoagulants (DOACs) can be considered for Child-Pugh A and Bpatients.
LMWH often preferred in Child-Pug-C.
Read the full review.”
Read the full review article here.
Article: Anticoagulation in cirrhosis
Authors: Lara Roberts
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 19, 2026, 16:59Rupam Manna: Not All Portal Vein Involvement in HCC Is the Same
-
Jul 19, 2026, 16:58Axel Cangas: Exploring the Future of Hemophilia Care at ISTH 2026
-
Jul 19, 2026, 16:58Aviva Schwartz: Air Pollution and Women’s Hematological Health in the Spotlight at ISTH 2026
-
Jul 19, 2026, 16:56Lola Sepot-Boucherit: Reimagining the Future of Rare Bleeding Disorders at ISTH 2026
-
Jul 19, 2026, 16:54Belén de la Morena Barrio: Presenting Our Research on Long-Read Sequencing for Genetic Diagnosis at ISTH 2026
-
Jul 19, 2026, 16:52Shamee Shastry: Sometimes the Answer is Not in the Test Tube Alone, but at the Patient’s Bedside
-
Jul 19, 2026, 16:52Manuela Albisetti: Congratulations to Alessandra Bosch on an Outstanding ISTH 2026 Talk
-
Jul 19, 2026, 16:44Fernanda Orsi: A Memorable Week of Science and Collaboration at ISTH 2026
-
Jul 19, 2026, 16:37William Aird: A Visual Guide to Understanding von Willebrand Disease